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PreviewsHoming in on Intracellular A?
In this issue of Neuron, a study by Billings et al.
points to intracellular A as a possible cause of neu-
ronal dysfunction. In a mouse model of Alzheimer’s
disease, Billings et al. link appearance of intraneuro-
nal A to cognitive impairments and then show that
“clearance” of intraneuronal A by anti-A antibodies
restores cognitive deficits.
Alzheimer's disease (AD) is characterized by a pro-
gressive decline in cognitive abilities. Especially pro-
found are the deficits in learning and memory. Ana-
tomic and pathologic correlates of these functional
deficits are apparent in the postmortem human AD
brain. Neuronal dystrophy and death are observed in
brain regions critical for these functions, as are the
other pathological hallmarks of AD, namely senile
plaques, neurofibrillary tangles, and gliosis. The rela-
tionship between pathological abnormalities and cog-
nitive deficits in early stages of Alzheimer’s disease
(e.g., mild cognitive impairment [MCI]) is less well
established. However, studies of glucose metabolism
in the brains of APOE4 carriers at risk for AD (Small
et al., 1995), longitudinal volumetric brain imaging of
individuals with presenilin mutations as they convert to
AD (Fox et al., 2001), and postmortem analysis of pa-
tients with MCI (Morris and Price, 2001) all suggest that
pathological features of AD are likely to be present
within vulnerable brain regions prior to the appearance
of detectable cognitive changes.
Though it is widely believed that the process that re-
sults in accumulation of Aβ as amyloid triggers the
complex pathological changes that ultimately lead to
cognitive dysfunction, there is great debate as to the
form or forms of Aβ that damage the brain. In addition
to its accumulation as amyloid in senile plaques and
cerebral vessels, Aβ accumulates in structurally and
morphologically distinct deposits. Aβ is found in diffuse
plaques that are recognized by antibodies but not amy-
loid dyes; these diffuse plaques are also present in nor-
mal aging and are not associated with other pathologi-
cal changes. The highly amyloidogenic 42 amino acid
form of Aβ (Aβ1-42) and amino-terminally truncated
forms of Aβ1-42 (Aβ42) are the predominant species of
Aβ typically found in both types of plaques; however,
many other forms of Aβ (e.g., Aβ1-40) are also present.
Aβ42 also selectively accumulates within vulnerable
neuronal populations. Intraneuronal Aβ42 is an early pa-
thologic feature. It is reported to be the first site of Aβ
accumulation in individuals with Trisomy 21, who would
invariably develop further AD-like changes in their
brain, and is also detected at autopsy of patients with
MCI. Animal model and cell culture studies suggest that
intraneuronal Aβ42 is quite toxic, although the physio-
logic relevance of these studies can be questioned. Ad-ditionally, soluble Aβ aggregates referred to as oligo-
mers or ADDLs appear to accumulate in the AD brain.
These soluble aggregates have been shown to be po-
tent neurotoxins that can acutely disrupt neuronal func-
tion in vivo. The limited immunohistochemical studies
using antibodies that recognize these oligomers or
ADDLs suggest that these forms of Aβ bear no spatial
relationship to either compact or diffuse plaques
(Kayed et al., 2003; Klein et al., 2004).
One of the values of studying learning and memory
in animal models of human neurodegenerative diseases
is the ability to potentially relate cognitive and physio-
logic alterations to the pathological alterations in the
brain. Such studies may ultimately provide a better un-
derstanding of the factors that lead to cognitive dys-
function in mice, reveal novel therapeutic targets, and
enable preclinical testing of therapeutic strategies
through cognitive endpoints. In this respect, the manu-
script by Billings and colleagues (2005 [this issue of
Neuron]), which provides a detailed cognitive charac-
terization of the 3xTg-AD mouse model of AD, is a valu-
able contribution to the AD field. This model expresses
both the AD-linked mutant APPNL and FTDP-17-linked
mutant tau P301L transgenes in a presenilin-1 mutant
knockin background. A series of lucid and well-designed
behavioral experiments that separate the effects of the
transgene(s) from possible nonspecific effects on other
behavioral systems are reported.
The authors evaluate the 3xTg-AD mice using a hip-
pocampal-dependent reference memory version of the
Morris water maze and an amygdala- and hippocam-
pal-dependent passive avoidance test. Using cross-
sectional and longitudinal testing paradigms, the au-
thors establish the onset and progression of cognitive
decline, at the same time controlling for carryover of
learned information in repeatedly tested groups of
mice. The authors find that 2-month-old 3xTg-AD mice,
which lack any observable AD-like pathology, perform
as well as control mice. At 4 months of age, homozy-
gous 3xTg-AD mice have subtle impairment in long-
term memory. At this age, the homozygous mice have
prominent intraneuronal Aβ42 accumulations within the
hippocampus, amygdala, and cortex, but no detectable
extracellular Aβ or tau pathology. No cognitive deficits
were observed in 4-month-old hemizygous mice, but,
curiously, no data on intracellular Aβ are provided. At
6 months of age, homozygous 3xTg-AD mice showed
impairments in both short- and long-term memory,
whereas heterozygous 3xTg-AD mice showed only
impairment in long-term memory. By 6 months of age,
intracellular and extracellular amyloid deposits are pre-
sent in their brains but lack tangle pathology.
Based on the immunocytochemical studies, the earli-
est AD-like pathology present in homozygous 3xTg-AD
mice is the appearance of intraneuronal Aβ42 in the
hippocampus, amygdala, and cortex by 4 months of
age. To examine the relationship between the intraneu-
ronal Aβ and the cognitive deficits, 4-month-old mice
were administered intracerebroventricular injections of
an anti-Aβ antibody and tested 7 days later. Antibody
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640administration reversed the impairment in the memory b
iretention in the water maze but not in the passive inhi-
bition test and also markedly reduced intraneuronal h
tAβ42 in the hippocampus but not in the amygdala.
Thus, there is a compelling association between intra- p
bneuronal Aβ42 accumulation and behavioral alterations,
but whether such data prove a cause and effect rela- b
stionship is likely to be debated. Indeed, these provoca-
tive studies probably raise more issues about intracel-
lular Aβ than they answer.
In many mutant APP transgenic mice, intracellular
Aβ42 accumulation has been detected, but relative to
the impressive accumulation reported in the 3xTg-AD
mice it is generally not a prominent pathologic feature
(see Table 1 and Figure 1). In contrast, transgenic mice
and rats expressing both mutant APP and PS typically
exhibit more prominent intraneuronal Aβ42 immuno-
reactivity at a fairly early age. Yet, all of these models
exhibit behavioral alterations that are at least superfi-
cially and qualitatively quite similar, and though the on-
set of the behavioral phenotype varies from model to
model, so too does the onset of all forms of Aβ deposi-
tion and other pathologies (Ashe, 2001; Janus and
Westaway, 2001). The apparent lack of truly distinct be-
F
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havioral phenotype in these various transgenic animals N
tcould be explained in a number of ways. Differences inTable 1. Behavioral Characteristics of Representative Transgenic Mice and Rat Models of AD
Extracellular Aβ Deposit
Tg Line Transgene(s) Reported Cognitive Defects Onset (Months) Intraneuronal Aβ
Tg2576 Swedish (K670N, M671L) 1. spontaneous alternation (Y maze) 7–8 sparse
2. reference memory (WM)
3. alternation rate (T maze)
4. cue learning (WM)
5. fear conditioning (CFC)
TgCRND8 Swedish + Indiana V717F 1. reference memory (WM) 3 not reporteda
2. short-term memory (RAM)
3. Pavlovian conditioning (CTA)
TgAPP/Ld/2 London (V717I) 1. reference memory (WM) 13–18 not reporteda
2. object recognition
TgPDAPP Indiana V717F 1. reference memory (RAM) 6 sparse
2. working memory (RAM)
3. object recognition
TghAPPFAD (J20) Swedish, Indiana V717F 1. reference memory (WM) 5–7 not reporteda
Tg (mThy1-hAPP751) London, Swedish 1. reference memory (WM) 3–4 not reporteda
TgAPP23 Swedish 1. reference memory (WM) 6 not reporteda
Tg2576/PS1 (e.g., Swedish + PS1 1. alternation rate (Y maze) 6 prominent
[M146L]) 2. increased activity in Y maze
3. short-term memory (RAM/WM)
4. reference memory (WM)
3xTg-AD Swedish APP, P301 tau PS1 1. reference memory (WM) 6 prominent
M146V knockin 2. fear conditioning (PI)
TgUKUR25 (rat model) 1. reference memory (WM)—mild absent prominent
impairment
a “Not reported” leaves open the possibility that intraneuronal Aβ is present in these mice. However, it is likely that it is not a prominent
feature. WM, Morris water maze; RAM, radial arm maze (dry land or water version); CFC, contextual fear conditioning; PI, passive inhibition;
CTA, conditioned taste aversion.howed similar phenotypes, then one could conclude
igure 1. Lack of Prominent Intracellular Aβ42 in the Cortex of a
-Year-Old Tg2576 APP NL Mouse
o counterstain is used, and the vast majority of neurons nega-
ively stain for Aβ. At this age, cognitive impairments are present.ehavior (besides age of onset of impairment) may ex-
st that have not been detected. Alternatively, the be-
avioral tests used to date may simply lack sensitivity
o detect subtle, but real, differences in the cognitive
henotypes. In either case, truly rigorous side-by-side
ehavioral evaluation of these various models has not
een performed. If such testing were performed and
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641either (1) that the intraneuronal Aβ42 accumulation is
more of a marker associated with the presenilin trans-
gene and not causally linked to the behavioral alterna-
tion or that (2) that much lower levels of intraneuronal
Aβ42 can cause neuronal dysfunction in the APP-only
mice. Alternatively, a quantitatively worse phenotype in
the mutant PS × mutant APP mice would support but
not prove the assertion that intracellular Aβ42 contrib-
utes to or causes the observed behavioral alterations.
The rather remarkable observation that administra-
tion of anti-Aβ antibody reverses accumulation of Aβ42
within the hippocampal neurons and improves the defi-
cit in spatial long-term memory assessed in the water
maze is perhaps the most intriguing observation in the
current study. Although the authors use this data to
support their conclusion that intraneuronal Aβ causes
the behavioral deficits, without a precise mechanistic
understanding of how the antibody is working, other
possible explanations for this relationship need to be
considered. In this regard, it will be important to deter-
mine the source of the intracellular Aβ and whether the
antibody is acting directly on intracellular Aβ42. Al-
though it is theoretically plausible to postulate that the
antibody is present within the neuron and binding Aβ in
manner that results in its clearance, there are no data
to support such a mechanism. Thus, it is more plausible
to suggest that the antibody is binding extracellular
Aβ42. If the source of intraneuronal Aβ is actually up-
take of secreted Aβ42, then it is possible that the anti-
body binding prevents its entry into the cell. However, if
intraneuronal Aβ42 is derived directly from intracellular
processing of APP, then it is more likely that the anti-
body is indirectly altering intraneuronal Aβ42. Indeed, it
may be that the intracellular Aβ42 observed in the
3xTg-AD mice is simply a response to extracellular Aβ
that can be “cleared” by the antibody.
In order to distinguish among these possible mecha-
nisms, several additional experiments need to be con-
ducted. First, careful studies examining whether the
anti-Aβ antibody gets into the neuron are needed. Se-
cond, the precise subcellular localization of the intra-
neuronal Aβ42 needs to be established. In this study, a
diffuse cytoplasmic accumulation of Aβ42 is noted.
This pattern of staining is quite distinct from the intra-
neuronal Aβ42 staining reported in humans with AD and
in other AD mouse models in which most intraneuronal
Aβ42 appears to accumulates in punctuate deposits
within multivesicular bodies and lysosomes (Takahashi
et al., 2002). Extracellular aggregated Aβ42 can accu-
mulate within lysosomes following endocytosis (Yang
et al., 1995). Alternatively, there is some evidence that
oxidative stress can result in diffuse cytoplasmic ac-
cumulation of intracellular Aβ42 that appears to be
derived directly from intracellular processing of APP
(Ohyagi et al., 2000). Thus, there is some precedence
for intraneuronal Aβ42 being a marker of stress, and not
necessarily the cause of it. In any case, understanding
where the intraneuronal Aβ42 accumulates in these
mice may provide additional insight into the role that it
plays in mediating the cognitive alterations.
A final caveat that concerns any study of intracellular
Aβ42 is whether staining with an Aβ42-selective anti-
body is sufficient proof that the peptide detected is
Aβ42. Most if not all Aβ42-selective antibodies crossreact to some degree with fragments of APP such as
those generated following β-secretase cleavage that
contain the Aβ42 sequence. Although biochemical and
mass spectroscopic methods can be used to confirm
the presence of Aβ42, using this technique to confirm
the presence of intercellular Aβ42 in the brain is prob-
lematic, as the extraction techniques invariably mix the
extracellular and intracellular pools. Thus, to detect
Aβ42 in situ it is important to use a panel of antibodies
that can detect other APP fragments. Lack of staining
with these antibodies can provide some assurance that
Aβ42 is in fact being detected.
Given the mechanistic questions raised, it may be
premature to conclude that intracellular Aβ42 causes
the observed behavioral deficits in 3xTg-AD mice.
However, even if it is shown that intraneuronal Aβ42 is
a consequence of extracellular stress induced perhaps
by small soluble aggregates of Aβ not detectable by
standard immunocytochemical methods, because of its
apparent toxicity intracellular Aβ42 could play a key
downstream role mediating neuronal dysfunction (La-
Ferla et al., 1995). Further study of the relationship be-
tween behavioral impairments in any animal model of
AD and Aβ accumulation, both inside and outside cells,
is needed in order to determine which form or forms of
Aβ are linked to neuronal dysfunction in mice. Finally,
the ultimate question for the field will be whether the
factors that cause cognitive changes in mouse models
of AD also cause cognitive changes in humans. This
question will probably be answered only by developing
selective therapies that target the causal factors in
mice and then determining whether such therapies are
effective in treating or preventing AD in humans.
Todd E. Golde and Christopher Janus
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